Terms: = Liver cancer AND KRAS, C-K-RAS, 3845, P01116, NS3, KI-RAS, KRAS2, K-RAS4A, K-RAS2A, K-RAS4B, KRAS1, K-RAS2B, RASK2 AND Treatment
529 results:
1. Single-cell transcriptome analysis reveals subtype-specific clonal evolution and microenvironmental changes in liver metastasis of pancreatic adenocarcinoma and their clinical implications.
Park JK; Jeong HO; Kim H; Choi JH; Lee EM; Kim S; Jang J; Choi DW; Lee SH; Kim KM; Jang KT; Lee KH; Lee KT; Lee MW; Lee JK; Lee S
Mol Cancer; 2024 May; 23(1):87. PubMed ID: 38702773
[TBL] [Abstract] [Full Text] [Related]
2. Decoding the Versatile Landscape of Autophagic Protein VMP1 in cancer: A Comprehensive Review across Tissue Types and Regulatory Mechanisms.
Renna FJ; Gonzalez CD; Vaccaro MI
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612567
[TBL] [Abstract] [Full Text] [Related]
3. Adagrasib treatment After Sotorasib-Related Hepatotoxicity in Patients With
Luo J; Florez N; Donnelly A; Lou Y; Lu K; Ma PC; Spira AI; Ryan D; Husain H
JCO Precis Oncol; 2024 Apr; 8():e2300644. PubMed ID: 38579193
[TBL] [Abstract] [Full Text] [Related]
4. NGS of brush cytology samples improves the detection of high-grade dysplasia and cholangiocarcinoma in patients with primary sclerosing cholangitis: A retrospective and prospective study.
Boyd S; Mustamäki T; Sjöblom N; Nordin A; Tenca A; Jokelainen K; Rantapero T; Liuksiala T; Lahtinen L; Kuopio T; Kytölä S; Mäkisalo H; Färkkilä M; Arola J
Hepatol Commun; 2024 Apr; 8(4):. PubMed ID: 38551383
[TBL] [Abstract] [Full Text] [Related]
5. Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM; Hofman MM; van der Horst TE; Paats MS; Heijboer FWJ; Aerts JGJV; Dumoulin DW; Cornelissen R; von der Thüsen JH; de Bruijn P; Hoop EO; Mathijssen RHJ; Koolen SLW; Dingemans AC
EBioMedicine; 2024 Apr; 102():105074. PubMed ID: 38507877
[TBL] [Abstract] [Full Text] [Related]
6. First-in-Class Humanized Antibody against Alternatively Spliced Tissue Factor Augments Anti-Metastatic Efficacy of Chemotherapy in a Preclinical Model of Pancreatic Ductal Adenocarcinoma.
Lewis CS; Backman C; Ahsan S; Cliff A; Hariharan A; Yeh JJ; Zhang X; Xie C; Sohal DPS; Bogdanov VY
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473827
[TBL] [Abstract] [Full Text] [Related]
7. Twelve-month progression-free survival with sotorasib and panitumumab in kras G12C mutant metastatic colorectal cancer.
Kavgaci G; Dizdar O; Yalcin S
Anticancer Drugs; 2024 Jun; 35(5):459-461. PubMed ID: 38451823
[TBL] [Abstract] [Full Text] [Related]
8. Improved survival of patients receiving immunotherapy and chemotherapy following curative-intent resection of colorectal liver metastases.
Pollini T; Tran T; Wong P; Adam MA; Alseidi A; Corvera C; Hirose K; Nakakura E; Warren R; Maker VK; Maker AV
J Gastrointest Surg; 2024 Mar; 28(3):246-251. PubMed ID: 38445916
[TBL] [Abstract] [Full Text] [Related]
9. Tumor location matters, next generation sequencing mutation profiling of left-sided, rectal, and right-sided colorectal tumors in 552 patients.
Ciepiela I; Szczepaniak M; Ciepiela P; Hińcza-Nowak K; Kopczyński J; Macek P; Kubicka K; Chrapek M; Tyka M; Góźdź S; Kowalik A
Sci Rep; 2024 Feb; 14(1):4619. PubMed ID: 38409377
[TBL] [Abstract] [Full Text] [Related]
10. Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database.
Karapetis CS; Liu H; Sorich MJ; Pederson LD; Van Cutsem E; Maughan T; Douillard JY; O'Callaghan CJ; Jonker D; Bokemeyer C; Sobrero A; Cremolini C; Chibaudel B; Zalcberg J; Adams R; Buyse M; Peeters M; Yoshino T; de Gramont A; Shi Q
Br J Cancer; 2024 May; 130(8):1269-1278. PubMed ID: 38402342
[TBL] [Abstract] [Full Text] [Related]
11. The association between kras and histopathological growth patterns and the impact on resection margins around vasculature and bile ducts in colorectal liver metastases.
Wong P; Wong GYM; Toon CW; Chapuis P; Hugh TJ
ANZ J Surg; 2024 Apr; 94(4):560-565. PubMed ID: 38366706
[TBL] [Abstract] [Full Text] [Related]
12. Application of plasma circulating kras mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract] [Full Text] [Related]
13. Ferroptosis: New Strategies and Ideas for the treatment of Pancreatic Ductal Adenocarcinoma.
Yang C; Dong Q; Bao H; Ge Y; Xu Z; Li J; Jiang X; Xu Y; Zhong X
Front Biosci (Landmark Ed); 2024 Jan; 29(1):45. PubMed ID: 38287825
[TBL] [Abstract] [Full Text] [Related]
14. Molecular Profile of Intrahepatic Cholangiocarcinoma.
Andraus W; Tustumi F; de Meira Junior JD; Pinheiro RSN; Waisberg DR; Lopes LD; Arantes RM; Rocha Santos V; de Martino RB; Carneiro D'Albuquerque LA
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203635
[TBL] [Abstract] [Full Text] [Related]
15. Clinical and Genomic Characterization of Long-Term Responders Receiving Immune Checkpoint Blockade for Metastatic Non-Small-Cell Lung cancer.
Ghanem P; Murray JC; Hsu M; Guo MZ; Ettinger DS; Feliciano J; Forde P; Hann CL; Lam VK; Levy B; Anagnostou V; Brahmer JR; Marrone KA
Clin Lung Cancer; 2024 Mar; 25(2):109-118. PubMed ID: 38161136
[TBL] [Abstract] [Full Text] [Related]
16. Precision medicine for kras wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
17. Regorafenib therapy as a third-line treatment for metastatic colorectal cancer: A single center long term experience.
Ozkan M; Oflazoglu U; Yildiz Y; Güc ZG; Salman T; Ünal S; Kücükzeybek Y; Alacacioglu A
Medicine (Baltimore); 2023 Dec; 102(50):e36435. PubMed ID: 38115370
[TBL] [Abstract] [Full Text] [Related]
18. KLK10 promotes the progression of kras mutant colorectal cancer via PAR1-PDK1-AKT signaling pathway.
Wu K; Wu B; Yan K; Ding Q; Miao Z
Cell Biol Int; 2024 Apr; 48(4):440-449. PubMed ID: 38115179
[TBL] [Abstract] [Full Text] [Related]
19. Sustained Disease Control in Immune Checkpoint Blockade Responders with Microsatellite Instability-high Colorectal cancer after treatment Termination.
Simmons K; Thomas JV; Ludford K; Willis JA; Higbie VS; Raghav KPS; Johnson B; Dasari A; Kee BK; Parseghian CM; Lee MS; Le PH; Morelli MP; Shen JP; Bent A; Vilar E; Wolff RA; Kopetz S; Overman MJ; Morris VK
Cancer Res Commun; 2023 Dec; 3(12):2510-2517. PubMed ID: 38085001
[TBL] [Abstract] [Full Text] [Related]
20. Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel kras P34R.
Chen R; Yang D; Liu Y; Wang B; Xu H
Anticancer Drugs; 2024 Feb; 35(2):195-198. PubMed ID: 38018809
[TBL] [Abstract] [Full Text] [Related]
[Next]
